[AMAG] AMAG Pharmaceuticals, Inc.


Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 35.8 Change: 1 (2.87%)
Ext. hours: Change: 0 (0%)

chart AMAG

Refresh chart

Strongest Trends Summary For AMAG

AMAG is in the medium-term down -38% in 5 months. In the long-term down -81% below S&P in 6 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: AMAG Pharmaceuticals, Inc. develops and commercializes specialty pharmaceutical products. The company markets Feraheme (ferumoxytol) injection for use as an intravenous (IV) iron replacement therapy for the treatment of iron deficiency anemia in adult patients with chronic kidney disease; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds. It markets Feraheme in the United States and Canada; and as Rienso in the European Union. The company sells Feraheme to authorized wholesalers and specialty distributors. AMAG Pharmaceuticals, Inc. has a license, development, and commercialization agreement with Takeda Pharmaceutical Company Limited to develop and commercialize Feraheme/Rienso as a therapeutic agent in Europe, certain Asia-Pacific countries, the Commonwealth of Independent States, Canada, India, and Turkey; and collaboration and exclusive license agreement with 3SBio for the development and commercialization of Feraheme as an IV iron rep

Fundamental Ratios
Shares Outstanding EPS1.11 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 385.93% Sales Growth - Q/Q38.41% P/E14.77
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA11.63% ROE26.74% ROI15.98%
Current Ratio1.71 Quick Ratio1.61 Long Term Debt/Equity1.51 Debt Ratio0.45
Gross Margin81.03% Operating Margin31.1% Net Profit Margin65.25% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities183.64 M Cash From Investing Activities-284.74 M Cash From Operating Activities71.69 M Gross Profit104.2 M
Net Profit33.26 M Operating Profit61.12 M Total Assets1.64 B Total Current Assets555.48 M
Total Current Liabilities323.97 M Total Debt483.2 M Total Liabilities926.3 M Total Revenue123.88 M
Technical Data
High 52 week25.65 Low 52 week10.34 Last close10.34 Last change-4.08%
RSI40.26 Average true range0.72 Beta0.76 Volume768.3 K
Simple moving average 20 days-8.89% Simple moving average 50 days-14.38% Simple moving average 200 days-41.9%
Performance Data
Performance Week-10.32% Performance Month-13.18% Performance Quart-38.12% Performance Half-56.92%
Performance Year-21.96% Performance Year-to-date-31.93% Volatility daily4.01% Volatility weekly8.97%
Volatility monthly18.39% Volatility yearly63.7% Relative Volume235.39% Average Volume747.72 K
New High New Low


2019-06-25 15:49:00 | Why Palatin Technologies Stock Dropped as Much as 21.5% Today

2019-06-25 14:00:00 | How Raleigh's Sprout can benefit from FDA's approval of another female sexual disorder drug

2019-06-24 17:45:09 | AMAG's Vyleesi Gets FDA NOD for Women with Low Sexual Desire

2019-06-24 16:19:00 | Palatin Jumps Then Pulls Back After FDA Clears Sexual-Desire Drug for Women

2019-06-24 13:58:00 | Another Women’s Libido Drug, Vyleesi, Won FDA Approval. Stock Investors Aren’t Happy.

2019-06-24 08:03:00 | Palatin's stock rockets after FDA OK to market sexual desire disorder treatment

2019-06-22 15:07:43 | The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs

2019-06-21 17:41:00 | AMAG stock rallies on FDA approval for drug to increase women's sex drive

2019-06-21 17:37:37 | Amag’s plan to bypass female libido drug pitfalls? Social media.

2019-06-21 17:23:08 | AMAG Pharmaceuticals Announces FDA Approval of Vyleesi™ Bremelanotide Injection for Acquired, Generalized Hypoactive Sexual Desire Disorder HSDD in Premenopausal Women

2019-06-20 09:00:01 | All You Need to Know About AMAG Pharmaceuticals AMAG Rating Upgrade to Buy

2019-06-10 09:39:01 | TherapeuticsMD Enters Agreement to Market Drugs Outside US

2019-06-06 09:31:01 | AMAG Pharmaceuticals AMAG Down 8.9% Since Last Earnings Report: Can It Rebound?

2019-06-05 15:45:00 | AMAG Pharmaceuticals Could Be Cut in Half Even From Here - Avoid

2019-05-29 08:00:00 | AMAG Pharmaceuticals to Present at Jefferies 2019 Global Healthcare Conference

2019-05-20 15:15:07 | Is AMAG Pharmaceuticals, Inc.'s NASDAQ:AMAG Balance Sheet A Threat To Its Future?

2019-05-20 05:21:09 | New Strong Sell Stocks for May 20th

2019-05-17 08:00:00 | AMAG Pharmaceuticals to Host Analyst Day on May 22, 2019 in New York

2019-05-10 10:31:02 | New Strong Sell Stocks for May 10th

2019-05-09 19:48:52 | Is AMAG Pharmaceuticals, Inc. AMAG A Good Stock To Buy?

2019-05-09 19:15:01 | Amag Pharmaceuticals Inc AMAG President & CEO William K Heiden Bought $107,000 of Shares

2019-05-09 06:57:10 | AMAG Q1 Loss Wider Than Expected, Revenues Lag Estimates

2019-05-08 08:30:03 | Edited Transcript of AMAG earnings conference call or presentation 7-May-19 12:00pm GMT

2019-05-08 07:53:50 | The Daily Biotech Pulse: Daiichi's Positive Breast Cancer Trial, Supernus Slumps, Axovant Reverse Split

2019-05-07 13:23:24 | AMAG Pharmaceuticals Inc AMAG Q1 2019 Earnings Call Transcript

2019-05-07 08:35:12 | AMAG Pharmaceuticals AMAG Reports Q1 Loss, Lags Revenue Estimates

2019-05-07 07:28:34 | AMAG Pharmaceuticals: 1Q Earnings Snapshot

2019-05-07 07:00:00 | AMAG Pharmaceuticals Announces First Quarter 2019 Financial Results and Provides Corporate Update

2019-05-03 08:00:00 | AMAG Pharmaceuticals Presents New Data at the American College of Obstetricians and Gynecologists Annual Meeting 

2019-04-30 08:05:00 | AMAG Pharmaceuticals to Host First Quarter 2019 Financial Results Conference Call and Webcast on Tuesday, May 7, 2019 at 8:00 a.m. ET

2019-04-30 08:00:00 | AMAG Pharmaceuticals Announces Grant of Inducement Awards Under NASDAQ Listing Rule 5635c4

2019-04-25 10:34:02 | AMAG Pharmaceuticals AMAG May Report Negative Earnings: Know the Trend Ahead of Q1 Release

2019-04-16 08:00:00 | AMAG Pharmaceuticals Appoints Nancy Griffith, PH.D., as Vice President of Scientific Communications and Medical Operations

2019-04-12 09:01:42 | The AMAG Pharmaceuticals NASDAQ:AMAG Share Price Is Down 51% So Some Shareholders Are Wishing They Sold

2019-04-12 08:00:00 | AMAG Pharmaceuticals Appoints New Members to Board of Directors

2019-04-02 08:00:00 | AMAG Pharmaceuticals to Present at Needham 18th Annual Healthcare Conference

2019-03-20 08:00:00 | March of Dimes and AMAG Pharmaceuticals, Inc., Announce First Joint Supportive Pregnancy Care Program

2019-03-18 12:43:33 | New Doubt on Treatment to Prevent Preterm Birth

2019-03-13 10:46:02 | Biotech Stock Roundup: REGN Gets FDA Nod for Dupixent & Other Pipeline News

2019-03-11 10:35:02 | AMAG's Stock Down as Pregnancy Drug Fails in PROLONG Study

2019-03-09 09:31:02 | Why Is AMAG Pharmaceuticals AMAG Down 24.5% Since Last Earnings Report?

2019-03-08 11:26:41 | Amag's shares fall after $323M pregnancy drug fails in post-approval trial

2019-03-08 09:00:00 | AMAG Pharmaceuticals stock down 6% after latest trial of Makena fails to meet primary endpoints

2019-03-08 08:00:00 | AMAG Pharmaceuticals Announces Topline Results From the PROLONG Trial Evaluating Makena® hydroxyprogesterone caproate injection

2019-03-07 08:00:00 | AMAG Pharmaceuticals Presents New Data on Bremelanotide and Hypoactive Sexual Desire Disorder at the ISSWSH/ISSM Joint Meeting

2019-03-05 08:00:00 | AMAG Pharmaceuticals to Present at Upcoming Investor Conferences

2019-03-01 15:48:25 | AMAG Pharmaceuticals Inc AMAG Files 10-K for the Fiscal Year Ended on December 31, 2018

2019-02-28 12:31:49 | Antares Pharma Inc ATRS Q4 2018 Earnings Conference Call Transcript

2019-02-19 08:00:00 | AMAG Pharmaceuticals to Present at Leerink Partners Global Healthcare Conference

2019-02-08 20:59:18 | AMAG Pharmaceuticals AMAG Q4 2018 Earnings Conference Call Transcript